MRNA Forex News
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants
The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews
|
88 days ago
Moderna Says CHMP Recommends Marketing Authorization For MRESVIA RSV Vaccine In EU
Moderna, Inc. (MRNA) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
RTTNews
|
144 days ago
Moderna Reports Positive Phase 3 Data For Flu And COVID Combination Vaccine
Moderna, Inc. (MRNA) announced Monday that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints. Moderna is the only company with a positive Phase 3 flu and COVID combination vaccine.
RTTNews
|
161 days ago
Moderna Stock Up 6% As Q4 Results Top Estimates
Biotechnology company Moderna reported a profit for the fourth quarter that plunged from last year, reflecting a sharp drop in COVID-19 vaccines sales. However, both earnings per share and revenues for the quarter topped analysts' expectations. The company also reaffirmed its 2024 product sales outlook.
RTTNews
|
270 days ago
CDC Recommends Updated Pfizer, Moderna COVID-19 Vaccine
The Centers for Disease Control and Prevention or CDC has recommended everyone 6 months and older to get an updated COVID-19 vaccine ahead of the virus season this fall and winter. The agency expects the updated COVID-19 vaccines from Pfizer-BioNTech and Moderna, which was approved by the U.S. Food and Drug Administration earlier this week, to be available later this week.
RTTNews
|
433 days ago
Moderna, Immatics Ink Strategic Multi-Platform Collaboration To Develop Oncology Therapeutics
Biopharmaceutical company Moderna, Inc. (MRNA) and Germany-based Immatics N.V. (IMTX) announced Monday a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
RTTNews
|
435 days ago
Moderna Says Clinical Trial Data Shows Updated COVID Vaccine Very Effective Against BA.2.86 Variant
Moderna, Inc. (MRNA) announced Wednesday that clinical trial data from its research assay confirm its updated COVID-19 vaccine generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 (Pirola), a variant under monitoring.
RTTNews
|
439 days ago
FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines
The U.S. Food and Drug Administration said it has amended the emergency use authorizations or EUAs of COVID-19 bivalent mRNA vaccines of ModernaTX Inc. and Pfizer-BioNTech to simplify the vaccination schedule for most individuals. With the changes, the current bivalent vaccines, for original and omicron BA.4/BA.5 strains, can be used for all doses administered to individuals 6 months of age and...
RTTNews
|
580 days ago
FDA Advisors Propose To Replace Primary COVID Shots With New Bivalent Shots
The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
RTTNews
|
662 days ago
Moderna Says Both Bivalent Omicron-targeting Booster Candidates Trigger Superior Antibody Response
Biotechnology company Moderna, Inc. (MRNA) announced Monday that both of Moderna's bivalent Omicron-targeting booster candidates, mRNA-1273.214 and mRNA-1273.222, trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4/BA.5) in Phase 2/3 clinical trials.
RTTNews
|
735 days ago
